Abbott: FDA clears first first commercially available TBI blood test

Abbott has received U.S. FDA clearance for what will be the first commercially available laboratory traumatic brain injury blood test, making it widely available to hospitals in the United States. The test, which runs on Abbott’s Alinity i laboratory instrument, will provide clinicians with an objective way to quickly assess individuals with mild TBIs, also known as concussions. Abbott’s Alinity i TBI lab test offers a new reliable result in 18 minutes to help clinicians quickly assess concussion and triage patients. For those with negative results, it rules out the need for a CT scan and can eliminate wait time at the hospital. The test measures two biomarkers in the blood that, in elevated concentrations, are tightly correlated to brain injury.